Abiopharma

🔍 Lurker Nancy (Executive)

Company: EyePoint, Inc. (EYPT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 12,666 shares of Common Stock (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: false | shares_owned_after: 219,213.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 126,889.00 | Footnotes: F1
• Acquired 40,000 shares of Stock Option (Right to Buy) at $17.48 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | Exercise: 2027-01-02 | equity_swap_involved: false | shares_owned_after: 40,000.00 | transaction_form_type: 4
• Sold 12,666 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-05 | Code: M | equity_swap_involved: false | shares_owned_after: 12,667.00 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F2: The restricted stock units vest in three ratable annual installments beginning January 5, 2025.